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Our understanding of the active role that astrocytes play in modulating neuronal function and behavior is rapidly expanding, but little is
known about the role that astrocytes may play in drug-seeking behavior for commonly abused substances. Given that the nucleus
accumbens is critically involved in substance abuse and motivation, we sought to determine whether nucleus accumbens astrocytes
influence the motivation to self-administer ethanol following abstinence. We found that the packing density of astrocytes that were
expressing glial fibrillary acidic protein increased in the nucleus accumbens core (NAcore) during abstinence from EtOH self-
administration. No change was observed in the nucleus accumbens shell. This increased NAcore astrocyte density positively correlated
with the motivation for ethanol. Astrocytes can communicate with one another and influence neuronal activity through gap-junction
hemichannels. Because of this, the effect of blocking gap-junction hemichannels on the motivation for ethanol was examined. The
motivation to self-administer ethanol after 3 weeks abstinence was increased following microinjection of gap-junction hemichannel
blockers into the NAcore at doses that block both neuronal and astrocytic channels. In contrast, no effect was observed following
microinjection of doses that are not thought to block astrocytic channels or following microinjection of either dose into the nucleus
accumbens shell. Additionally, the motivation for sucrose after 3 weeks abstinence was unaffected by NAcore gap-junction hemichannel
blockers. Next, Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) were selectively expressed in NAcore
astrocytes to test the effect of astrocyte stimulation. DREADD activation increased cytosolic calcium in primary astrocytes, facilitated
responding for rewarding brain stimulation, and reduced the motivation for ethanol after 3 weeks abstinence. This is the first work to
modulate drug-seeking behavior with astrocyte-specific DREADDs. Taken together, our findings demonstrate that NAcore astrocytes
can shape the motivation to self-administer ethanol; suggesting that the development of ligands which selectively stimulate astrocytes may
be a successful strategy to abate ethanol-seeking behavior.


































































Addiction is associated with adaptive changes within
discrete brain structures. Similar to neurons, astrocytes
display temporally and regionally specific adaptations to
abused substances. Astrocytic adaptations are commonly
measured via immunoreactivity of the structural filament
glial fibrillary acidic protein (GFAP) (Sofroniew and Vinters,
2010). For example, total GFAP expression and the number
of cells expressing GFAP (GFAPþ ) increased in the nucleus
accumbens core (NAcore) after repeated cocaine injections,
but no change was observed in the dorsal striatum (Bowers
and Kalivas, 2003). Additionally, rat strains that had self-
administered more morphine expressed more GFAP in the
ventral tegmental area (Beitner-Johnson et al, 1993). In the
prefrontal cortex, prelimbic GFAPþ astrocyte density was
lower in rats that exhibited higher ethanol (EtOH) preference
(Miguel-Hidalgo, 2005) while dorsolateral astrocyte density
was lower in EtOH-dependent humans (Miguel-Hidalgo et al,
2002). These studies illustrate that astrocytes respond to
commonly abused substances in a region-specific manner.
Astrocytes are the predominant mammalian brain cell
type, but because they do not fire action potentials, the
capacity of astrocytes to modulate complex behaviors was
only recently appreciated. It is now known that astrocytes
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can release transmitter through exocytosis (Parpura et al,
1994), transporters (Szatkowski et al, 1990), gap-junction
hemichannels (Ye et al, 2003), and ion channels following
stimulation of G-protein-coupled receptors (Woo et al,
2012). Notably, manipulations of astrocytic transporters,
which increased extracellular transmitter, reduced respond-
ing for rewarding brain stimulation (John et al, 2012)
and blocked the reinstatement of cocaine-seeking behavior
(Baker et al, 2003). Moreover, the reinstatement of cocaine-
seeking behavior did not occur in transgenic mice expressing
a dominant-negative SNARE domain in astrocytes (Turner
et al, 2012). These mice exhibit deficient gliotransmission as
well as disruptions in the expression and/or function of cell-
surface proteins, including ion channels, transporters, and
receptors. Together, these studies suggest that specific routes
of astrocytic transmitter flux can differentially influence the
seeking of drug and rewarding brain stimulation.
We sought to determine whether nucleus accumbens
astrocytes can influence the motivation to self-administer
EtOH after abstinence. The nucleus accumbens is com-
prised of at least two anatomically and functionally distinct
subregions: the NAcore and the shell (NAshell; Zahm,
2000). The NAcore is implicated in the control of behavior
by discrete cues, while the NAshell is implicated in the
control of behavior by spatial/contextual information as
well as primary reinforcement (Chaudhri et al, 2010; Pierce
and Kumaresan, 2006). This study focused on the NAcore
because activation of the human NAcore by drug-related
stimuli is predictive of relapse risk (Heinz et al, 2009).
Several studies have examined the ability of different stimuli
to provoke drug-seeking behavior using the extinction-
reinstatement paradigm. Alternatively, abstinence is im-
posed as humans do not typically undergo explicit
extinction of drug-related stimuli and behaviors (Epstein
et al, 2006). Our hypothesis was that NAcore astrocytes
modulate the motivation to self-administer EtOH after
abstinence. To test this hypothesis, we employed a loss- and
gain-of-function approach and quantified motivation via
breakpoint obtained on an EtOH-maintained progressive
ratio reinforcement schedule (Richardson and Roberts,
1996). For loss-of-function studies, gap-junction hemichan-
nel blockers were microinjected into the NAcore. The
abundance of gap-junction hemichannels in astrocytes
enable both extracellular (Hassinger et al, 1996) and
intracellular (Dermietzel and Spray, 1993) communication
through large networks of electrically coupled astrocytes.
However, gap-junctions are found in many cell types, and
their ligands are pharmacologically promiscuous. There-
fore, we also performed gain-of-function studies using
Designer Receptors Exclusively Activated by Designer
Drugs (DREADDs) that were selectively expressed in
NAcore astrocytes. The impact of astrocytic DREADD




Procedures were IACUC approved and compliant with the
NIH Guide for the Care and Use of Laboratory Animals.
Male rats (Harlan, Dublin VA: 225–250 g Han Wistar for
EtOH; 250–290 g Sprague Dawley for ICSS) were individu-
ally housed (lights on 06:00 am) with ad libitum home cage
food and water, unless indicated. Habituation and surgical
recovery were 1 week each.
Reagents
In vivo: EtOH (20%, v/v, from 95%) and/or sucrose (2%,
w/v) were diluted in water. 18-a-glycyrrhetinic acid (18a:
100 mM) and mefloquine (25 or 750 mM), both obtained
from Sigma (St Louis, MO), were dissolved in 0.05% DMSO/
PBS. Clozapine-N-oxide (CNO, obtained from NIDDK) was
dissolved in 0.5% DMSO/saline. Cocaine (obtained from
NIDA) was dissolved in saline. In vitro: AAV5 was diluted
in serum-free media (SFM, 4 109 particles/ml), rhod-2 AM
(Invitrogen, Grand Island, NY) was dissolved in 0.05%
DMSO/pluronic in SFM. CNO and (S)-DHPG (Tocris,
Bristol, UK) were dissolved in saline.
Vector
rAAV5/GFAP-HA-hm3D-IRES-mCitrine: HA-hM3D (Gaq)
was inserted upstream of IRES-mCitrine.pcDNA3 and
subcloned into pAAV5 containing the minimal human
GFAP promoter with SalI and EcoRI. Purified virus was
obtained pre-dialyzed (350 mM NaCl, 5% D-sorbitol in PBS,
UNC Gene Therapy Center, Chapel Hill, NC) and micro-
injected at 4 1012 particles/ml, 1 ml/side over 10 min, and
7 min allowed for diffusion. Testing began 2 weeks later.
The volume of transfected cells was determined with serial
sections using the method of Cavalieri (Gundersen and
Jensen, 1987; Stereologer, SRC, Tampa, FL).
Caþþ Measures
Primary astrocytes were prepared as previously described
(Zou et al, 2011) and are detailed in Supplementary
Methods. Cells were transfected (100 ml AAV5: Gaq-
DREADD or GFP) and cytosolic calcium ([Caþþ ]i)
measured 3–4 days later. On test day, media was changed
to SFM (1 h, 37 1C, 5% CO2) and cells loaded with rhod-2
(3 mM, 15 min, 30 1C, 5% CO2), as previously described (Sun
et al, 2013). After washing (SFM, 15 min), recordings were
obtained (AxioObserver Z.1, AxioVision 4.6, Zeiss, Ober-
kochen, Germany). Specifically, rhod-2 was excited (180 ms)
and emission sampled every second for a 30 s baseline and
then every 10 s thereafter (20x PlanApo, CCD) for 12 min to
avoid photobleaching. The relative cytosolic fluorescence of
24 individual cells was normalized to baseline and
experiments performed in duplicate. Sequential treatments
were CNO (1 nM, 12 min), SFM wash (30 min), re-baseline,
and (S)-DHPG (2 mM, 12 min). Doses were based upon
earlier reports (Ferguson et al, 2011; Toms and Roberts,
1999) and preliminary data (not shown).
Surgery
Stainless steel cannulae (26 gauge, AmazonSupply) and
obturators (33 gauge, AmazonSupply) or a polyamide-
insulated cathode (30 gauge, PlasticsOne, Roanoke, VA)
were implanted under isoflurane using the following coordi-
nates from bregma. NAcore: þ 1.2 AP, ±1.94 ML,  6.82 DV,
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6 1y; NAshell: þ 2.2 AP, ±2.35 ML,  6.25 DV, 8 1y; medial
forebrain bundle:  2.8 AP, þ 1.7 ML, and  8.8 DV from
skull surface. The cannulae were angled to avoid the lateral
ventricles. The anode was grounded to a skull screw.
Intermittent EtOH or Sucrose Access
Procedures were previously described (Hopf et al, 2010) and
are detailed in Supplementary Methods. Subject handling
continued during the 3 weeks abstinence period.
Operant EtOH Self-Administration
As per procedures adapted from prior reports (Bowers et al,
2008), rats were water deprived during shaping that began
with two, 15 h, fixed ratio one sessions (FR1) for 10%
sucrose (w/v) in 20% EtOH (v/v). After these sessions, 1–2 h
home cage water was allowed. Next, rats were trained to
respond on a FR3 for one to three, 1 h sessions per stage: (1)
10% sucrose/20% EtOH, 3–4 h home cage water; (2) 5%
sucrose/20% EtOH, 5–6 h water; (3) 3% sucrose/20% EtOH,
ad libitum home cage water; (4) 1.5% sucrose/20% EtOH,
ad libitum water; (5) 8 weeks of contiguous daily sessions
for 0% sucrose/20% EtOH and ad libitum home cage water.
Subject handling continued during the 3 weeks abstinence
period.
Breakpoint
Procedures for the determination of the cue-provoked and
EtOH-maintained breakpoint were previously described
(Bowers et al, 2008) and are detailed in Supplementary
Methods. Breakpoint was defined as total active-lever
depressions in the last completed ratio. Thus, lever depres-
sions that did not yield reinforcer delivery were not
included in breakpoint calculations. Sessions timed out
after 15 min of inactivity, which generally occurred within
1 h. All drugs were administered in a counterbalanced
fashion. Mefloquine (25–750 mM), 18-a (100 mM), or vehicle
were microinjected (0.5 ml/side at 0.25 ml/min) with an
additional 2 min allowed for diffusion. CNO (3 mg/kg) or
vehicle was administered (1 ml/kg, i.p.), and experiments
occurred 30 min later.
ICSS
Rats were trained to respond for ICSS as previously described
(Bauer et al, 2013) and are detailed in Supplementary
Methods. Test sessions occurred 30 min after CNO (1.5–
6 mg/kg, i.p.) or immediately after cocaine (10 mg/kg, i.p.).
Histology
Tissue processing was adapted from prior reports (Long
et al, 1998) and are detailed in Supplementary Methods. All
groups were processed in parallel. Every 6th section was
collected via systematic-uniform random sampling and
incubated with anti-GFAP (1:15K, Dako, Carpinteria, CA;
4 1C, 15 h) prior to visualization (HRP and DAB, Vector
Labs, Burlingame, CA) and then Nissl counterstained.
GFAPþ cells were counted (blinded) using unbiased
stereological principles (Long et al, 1998; Stereologer, Zeiss
PlanApo 63x) and density obtained by dividing cell counts
by the measured brain volume. Immunofluorescent sections
were incubated (4 1C, 15 h) with Cy3-GFAP monoclonal
(1:800, Sigma) or b-tubulin-III (1:600, Abcam and then
1:1000 AF594, Invitrogen) and Hoescht-33342 counter-
stained (1:10K, 8 min).
Statistical Analysis
Run rate was defined as active-lever depressions-1/interval
duration. Stereology and breakpoint (defined above) were
analyzed by either a one- or two-way ANOVA, and time
course was analyzed by a repeated measures ANOVA.
Treatment and/or virus were factors. The primary ICSS-
dependent variable was reinforcement rate (stimulations/
min) normalized as percent Maximum Control Rate that
was analyzed by a two-way ANOVA with frequency and
post-virus day or treatment as factors. Significant main
effects were followed by a Bonferroni correction, Scheffé,
Dunnet’s, or Holm–Sidak post-hoc, as appropriate. Sig-
nificance was considered as po0.05.
RESULTS
NAcore GFAPþ Astrocyte Density Increased after
3 Weeks Abstinence from Ethanol
There is considerable interest in identifying adaptations
that develop during drug abstinence and which may drive
relapse. Here, astrocyte populations in the NAcore and
NAshell were examined after abstinence from EtOH self-
administration. These brain regions are critically involved
in EtOH relapse, and within these regions GFAP is restricted
to astrocytes.
As individual animal models cannot recapitulate the
entirety of alcohol use disorders (AUDs), astrocyte packing
density was measured following abstinence from two
distinct self-administration paradigms (Figure 1). Intermittent
EtOH access (EtOH-IA) models some cardinal features of
AUDs; eg, escalating consumption and preference (Hopf
et al, 2010). Operant EtOH self-administration models
the positive reinforcing and motivating effects of EtOH.
Figure 1a illustrates experimental timelines of these models.
We found that NAcore GFAPþ astrocyte density was sensi-
tive to abstinence time and treatment (Figure 1b, Supple-
mentary Figure S1A). More specifically, astrocyte density
increased 3 weeks after either EtOH-IA or operant EtOH,
but was unchanged 24 h after EtOH-IA. In contrast, NAcore
astrocyte density decreased 3 weeks after intermittent
sucrose (S-IA). Sucrose self-administration served as a
control for EtOH. Because altered NAcore astrocyte density
could reflect cell number or GFAP synthesis, GFAP protein
expression was measured in crude NAcore homogenate 3
weeks after operant EtOH self-administration. No change
was observed in GFAP expression (Supplementary Figure
S1B), suggesting that astrocyte packing density increased.
In contrast to the NAcore, NAshell astrocyte density
increased after either 24 h or 3 weeks abstinence from
EtOH-IA (Supplementary Figure S1C). However, NAshell
astrocyte density was unchanged 3 weeks after either
operant EtOH or S-IA (Supplementary Figure S1C). More-
over, no changes were noted in non-GFAPþ cell density or
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region volume for the NAcore (Figure 1c and d) or NAshell
(Supplementary Figure S1D and E).
Although GFAP is commonly used as an astrocytic
marker following pharmacological insult or injury (Eng
et al, 2000), GFAP antiserum does not label all astrocytes.
To better understand the response of NAcore astrocytes
during EtOH abstinence, we also measured aldehyde
dehydrogenase 1L1 (ALDH1L1) and glutamine synthetase.
ALDH1L1 appears to be expressed in all adult astrocytes,
but not other cell types (Cahoy et al, 2008). Glutamine
synthetase can protect neurons from excitotoxicity by
taking up and converting excess ammonia and glutamate
into glutamine. Glutamine synthetase antiserum labels all
cells in the astrocyte family including astrocytes, Bergmann
glia, Müller cells, tanycytes, and ependymal cells (Anlauf
and Derouiche, 2013). Of these, only the astrocytes are
found in the region analyzed. Neither the number of cells
expressing ALDH1L1 (Supplementary Figure S1G) nor
ALDH1L1 protein expression (Supplementary Figure S1H)
changed in the NAcore following EtOH self-administration.
This is in agreement with an immunoblotting study of
schizophrenic brain samples, which found increased GFAP
expression, but no change in ALDH1L1 expression com-
pared to controls (Feresten et al, 2013). In contrast,
Supplementary Figure S1I indicates that glutamine synthe-
tase expression increased in the NAcore after 3 weeks
abstinence from EtOH. These data support earlier work
showing increased packing density of glutamine synthetase-
positive astrocytes during abstinence from ethanol self-
administration (Miguel-Hidalgo, 2006).
The Ethanol Breakpoint Correlated with NAcore GFAPþ
Astrocyte Density
The NAcore is implicated in the motivational and cue-
reactivity aspects of AUDs (Heinz et al, 2009). Therefore,
we hypothesized that NAcore astrocytes contribute to the
motivation to self-administer EtOH after 3 weeks absti-
nence. To begin evaluating this hypothesis, ethanol self-
administration by formerly abstinent rats was provoked
by a compound cue that was previously associated with
EtOH availability (Bowers et al, 2008). The cue mimics
EtOH-associated olfactory, auditory, and visual stimuli that
contribute to the ‘first drink’ phenomenon. Similar stimuli
can precipitate relapse in alcoholics (Ludwig et al, 1974).
Figure 1e shows that the EtOH breakpoint positively
correlated with NAcore astrocyte density. Because break-
point is used as a proxy for motivation (Richardson and
Roberts, 1996), we subsequently examined if NAcore
astrocytes influence the motivation for EtOH.
Microinjection of Gap-Junction Hemichannel Blockers
into the NAcore Increased the Motivation to
Self-Administer Ethanol after 3 Weeks Abstinence
Figure 2a illustrates the experimental timeline. Astrocytes
express a large number of gap-junction hemichannels,
which are used for both extracellular (Hassinger et al, 1996)
and intracellular (Dermietzel and Spray, 1993) communica-
tion. As the motivation to self-administer EtOH positively
correlated with GFAPþ astrocyte number in the NAcore, we
tested the hypothesis that NAcore astrocytes can influence
EtOH self-administration by interfering with the capacity of
these cells to communicate through gap-junction hemi-
channels. Given that many cell types express structurally
similar gap-junction hemichannels, precise pharmacologi-
cal manipulation is not currently possible. Accordingly,
two gap-junction hemichannel blockers were examined in
separate cohorts: mefloquine or 18-a. Mefloquine blocks
neuronal gap-junction hemichannels at low doses, while
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Figure 1 NAcore GFAPþ astrocyte density increased after 3 weeks
abstinence from EtOH. (a) Experimental timeline. Five treatment groups
were analyzed: (i) age- and handling-matched naive, (ii) after 24 h
abstinence from EtOH-IA, (iii) after 3 weeks abstinence from EtOH-IA,
(iv) after 3 weeks abstinence from operant EtOH self-administration, and
(v) after 3 weeks abstinence from S-IA. (b) A significant one-way ANOVA
(F(4,25)¼ 13.74, p¼ 0.0001) followed by a Dunnett’s post-hoc indicated
that NAcore astrocyte density increased after 3 weeks abstinence from
either EtOH-IA or operant EtOH. Additionally, a significant decrease was
observed after 3 weeks abstinence from S-IA. No change was observed in
(c) non-GFAPþ cell density (p¼ 0.17) or (d) region volume (p¼ 0.92).
(e) Following 3-week abstinence, the EtOH breakpoint positively
correlated with NAcore astrocyte density for both the EtOH-IA
(R2¼ 0.87, p¼ 0.01) and operant EtOH cohorts (R2¼ 0.79, p¼ 0.04). In
contrast, no correlation was observed in the NAshell for either the EtOH-
IA (p¼ 0.89) or operant (p¼ 0.10) cohorts. M, Monday, etc.; abst, 3 weeks
abstinence; oper, operant. Data represent mean±SEM, *po0.05.
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10- to 100-fold higher doses also target astrocytes
(Cruikshank et al, 2004). NAcore neuronal gap-junction
hemichannel blockade alone did not influence the EtOH
breakpoint (Figure 2b). However, also targeting astrocytes
with a 30-fold higher mefloquine dose increased the EtOH
breakpoint. Additionally, microinjection of the relatively
selective gap-junction hemichannel blocker 18-a (Davidson
and Baumgarten, 1988) into the NAcore similarly increased
the EtOH breakpoint (Figure 2b). Although 18-a is not cell-
specific, it is intriguing that the EtOH breakpoint was
increased to the same extent by both the high mefloquine
dose and 18-a given that EtOH preference was similarly
increased by microinjection of either an astrocyte-specific
toxin or the same dose of 18-a (Miguel-Hidalgo et al, 2008)
that was used here. Importantly, while increased active-
lever responding was apparent throughout testing
(Figure 2c), no differences were observed in response rates
over the first several reinforcers earned (Figure 2d),
inactive-lever responding (Supplementary Figure S2A), or
latency to the first active-lever press (Supplementary Figure
S2B). These data suggest that gap-junction hemichannel
blockers did not produce obvious off-target motor effects
during EtOH self-administration. Supplementary Table S1
summarizes blood EtOH levels after the test session.
NAshell microinjection of either mefloquine dose did not
affect the EtOH breakpoint (Figure 2e). Additionally,
microinjection of the higher dose into the NAcore did not
influence the breakpoint of sucrose-abstinent rats for
sucrose (Figure 2f). Supplementary Figure S2C–E illustrates
microinjection sites. These data partially support our
hypothesis that NAcore astrocytes influence the motivation
to self-administer EtOH after abstinence. To further test this
hypothesis, we examined if NAcore astrocyte stimulation
impacts responding for ‘rewarding’ brain stimulation.
Stimulating NAcore Astrocytes Increased ICSS
Responding
Astrocytes predominantly respond to transmitter through
G-protein-coupled receptors, which increase [Caþþ ]i
(Porter and McCarthy, 1996). The most studied of these
receptors are Gaq-coupled. Given that astrocytes cannot be
pharmacologically isolated, we sought to determine whether
Gaq-DREADDs could be used to stimulate astrocytes.
DREADDs exhibit no basal activity, but are activated by
the selective agonist CNO (Armbruster et al, 2007).
Astrocyte-specific DREADDs were first tested in culture.
Figure 3a illustrates the experimental timeline where a
Caþþ -sensitive dye was loaded into primary astrocytes that
were expressing Gaq-DREADDs under the GFAP promoter
(Figure 3b). Bath application of CNO increased [Caþþ ]i in
primary astrocytes expressing Gaq-DREADD (Figure 3c),
but not if GFP was expressed instead (Figure 3c). (S)-DHPG,
a positive control and agonist of Gaq-coupled receptors,
increased [Caþþ ]i in both cultures (Figure 3d). These
in vitro data illustrate that activation of Gaq-DREADDs can
mobilize primary astrocyte [Caþþ ]i to a similar extent as
activation of endogenous Gaq-coupled receptors with (S)-
DHPG. These [Caþþ ]i elevations are similar to what others
have observed in primary astrocytes following (S)-DHPG
application (Toms and Roberts, 1999). Finally, a full
characterization of these astrocytic Gaq-DREADDs was
recently published (Agulhon et al, 2013). Among these
measures were [Caþþ ]i elevations that lasted tens of
seconds following brief application of CNO to a slice
preparation.
Next, we tested the hypothesis that stimulation of
astrocytic Gaq-DREADDs would alter responding for ICSS.
ICSS quantitatively estimates the impact of reward-altering
manipulations (Bauer et al, 2013). Figure 4a illustrates the
experimental timeline. Gaq-DREADDs were selectively
expressed in NAcore astrocytes extending B1 mm3 around
the injection site (Figure 4b and c, Supplementary Figure
S3A), which is less than half the estimated adult rat NAcore
volume (Wissman et al, 2012). Importantly, manipulating
any number of astrocytes can be consequential as an
astrocyte can associate with up to 105 synapses and





































































































750μM mefloquine25μM mefloquinevehicle 100μM 18-α
Experimental timeline progressive ratio
test: anion blockersurgery
Operant (EtOH)
1-2 wks 8 wks 3 wks 3 dy 3 dy
Figure 2 NAcore gap-junction hemichannel blocker microinjection
selectively increased the EtOH breakpoint. (a) Experimental timeline.
(b) Microinjection of gap-junction hemichannel blockers into the NAcore
increased the EtOH breakpoint (F(3,40)¼ 5.56, p¼ 0.003). A Scheffé post-
hoc revealed that breakpoint was only affected by 18-a or mefloquine
doses that target both neurons and astrocytes. Mefloquine doses that are
thought to only target neurons were without effect. No effect of treatment
order was found (p¼ 0.61). (c) Cumulative active-lever responding during
the test session. (d) A one-way repeated measures ANOVA did not
indicate differential response rates across initial reinforcer deliveries
(p¼ 0.98). Microinjection of mefloquine into the (e) NAshell did not alter
the EtOH breakpoint (p¼ 0.75) or the (f) sucrose breakpoint when
microinjected into the NAcore (p¼ 0.86). Data represent mean±SEM,
*po0.05.
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chromatolysis (Supplementary Figure S3B) suggested that
Gaq-DREADD expression did not cause overt toxicity.
While ICSS baseline was not affected by either Gaq-
DREADD expression or vehicle (Figure 4d), CNO signifi-
cantly facilitated ICSS (Figure 4e) at a dose previously used
to activate neuronal DREADDs (Ferguson et al, 2011). CNO
did not alter ICSS if Gaq-DREADD was not expressed or
other CNO doses were used (Supplementary Figure S3C–E).
As ICSS facilitation occurred within a timeframe (1.5 h)
where CNO back-conversion to clozapine has not been
shown (Guettier et al, 2009), CNO and astrocyte Gaq-
DREADD expression appear to be required. Importantly,
motoric capacity appeared unaltered because responding
was similar across treatments at both the lowest and highest
frequencies tested. Finally, ICSS was strongly facilitated by
the positive control cocaine regardless of Gaq-DREADD
expression (Supplementary Figure S3F). These results
suggest that NAcore astrocytes can modulate sensitivity to
rewarding stimulation. Accordingly, we examined if stimu-
lation of astrocytic Gaq-DREADDs that were expressed in
the NAcore shapes the motivation to self-administer EtOH
after 3 weeks abstinence.
Stimulating NAcore Astrocytes Decreased the
Motivation to Self-Administer Ethanol after 3 Weeks
Abstinence
Figure 5a illustrates the experimental timeline. The same
CNO dose found to facilitate ICSS (Figure 4e) was also
found to decrease the EtOH breakpoint in rats that had
Gaq-DREADDs expressed in NAcore astrocytes (Figure 5b).
CNO had no effect if GFP was expressed instead (Figure 5b).
Although Gaq-DREADD-expressing rats exhibited muted
responding after CNO administration (Figure 5c), motor
depressant effects were not apparent as response rates over
the first several reinforcers earned (Figure 5d), inactive-
lever responding (Figure 5e), and latency to the first active-
lever depression (Supplementary Figure S4A) were similar.
Supplementary Figure S4B and C illustrates cannulae
placements.
Experimental timeline
load Ca++ sensitive dye wash in SFM baseline CNO
15 min 15 min 30 s 12 min
wash in SFMwash in SFM baseline (S)-DHPG













































Figure 3 Activation of astrocytic Gaq-DREADDs increased [Caþþ ]i. (a) Experimental timeline. (b) Astrocytes expressing Gaq-DREADD and mCitrine
or GFP were loaded with the Caþþ -sensitive dye rhod-2. (c) After bath applying CNO, a one-way repeated measures ANOVA indicated that [Caþþ ]i
increased in astrocytes that were expressing Gaq-DREADD (vector: F(1,46)¼ 331.45, p¼ 0.001; time: F(69,3174)¼ 170.97, po0.0001; interaction:
F(69,3174)¼ 150.02, po0.0001). No change was observed in astrocytes expressing GFP. (d) Bath application of (S)-DHPG, a specific agonist of
endogenous Gaq-coupled receptors, increased [Caþþ ]i regardless of whether Gaq-DREADD or GFP was expressed. Following (S)-DHPG application, a
one-way repeated measures ANOVA revealed a small, but significant difference between transgenes (transgene: F(1,46)¼ 6.67, p¼ 0.01; time:
F(69,3174)¼ 284.47, p¼ 0.001; interaction F(69,3174)¼ 6.01, p¼ 0.0001). Arrow, onset of drug treatment; treatment bar, duration of drug treatment.
Data represent the mean of 24 cells normalized to baseline ±SEM.
Astrocytes guide responding for reward and ethanol




We found that NAcore astrocytes can shape behavioral
responding for rewarding stimuli as well as the motivation
to self-administer EtOH after 3 weeks abstinence. In brief,
GFAPþ astrocyte density increased in the NAcore after 3
weeks abstinence from EtOH, which positively correlated
with breakpoint. In a separate cohort, the EtOH breakpoint
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Figure 5 The motivation to self-administer ethanol after 3 weeks
abstinence was decreased by activation of astrocytic Gaq-DREADDs that
were expressed in the NAcore. (a) Experimental timeline. B) A one-way
ANOVA (F(2,30)¼ 3.29, p¼ 0.04) followed by a Scheffé post-hoc
indicated that 3 mg/kg CNO decreased the EtOH breakpoint in rats
expressing Gaq-DREADD compared to vehicle-treated rats expressing
Gaq-DREADD or CNO-treated rats that were expressing GFP.
(c) Cumulative active-lever responding during the test session. (d) A one-way
repeated measures ANOVA revealed no effect on response rates across
initial reinforcer deliveries (p¼ 0.39). (e) Inactive-lever responding was
not different (p¼ 0.21). NS, nonsignificant. Data represent mean±SEM,
*po0.05.
Figure 4 Responding for ICSS was facilitated by activation of astrocytic
Gaq-DREADDs that were expressed in the NAcore. (a) Experimental
timeline. (b) Low-magnification confocal images showing that Gaq-
DREADD was expressed in NAcore astrocytes. Note that similar
expression was observed in Gaq-DREADD transgenic mice (Agulhon
et al, 2013), and that GFAP antiserum detects a more limited number of
astrocyte processes. White arrow, transfected astrocyte; gray arrow, non-
transfected astrocyte. An example of the volume of transfected cells is
shown in Supplementary Figure S3. (c) High-magnification confocal images
chosen to show transfected astrocyte complexity and vector specificity.
(d) A two-way ANOVA revealed that ICSS was unaffected by vehicle
(p¼ 0.17) or post-transfection time (p¼ 0.29). (e) A moderate, but signifi-
cant ICSS facilitation was observed following 3 mg/kg CNO (frequency,
F(9,45)¼ 50.07, Po0.0001; treatment, F(1,5)¼ 13.55, p¼ 0.01). % MCR,
percent Maximum Control Rate. Data represent mean±SEM. Scale
bar¼ 50mm.
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increased following microinjection of gap-junction hemi-
channel blockers into the NAcore, but not NAshell. In
contrast, NAcore astrocyte-specific Gaq-DREADD activa-
tion facilitated ICSS and decreased the EtOH breakpoint.
Taken together, this work demonstrated the importance of
astrocyte biology in modulating the behavioral responses to
reinforcing stimuli and it is the first to use astrocyte-specific
designer receptors to reduce ethanol self-administration.
Behavioral Relevance of Astrocyte Density
This study revealed that NAcore astrocyte density responded
uniquely during abstinence from sucrose compared to
EtOH. While not proof of causation, the positive correlation
of NAcore astrocyte density with the EtOH breakpoint
supported our hypothesis that NAcore astrocytes shape the
motivation to self-administer EtOH after abstinence for at
least three reasons. First, the NAcore is critically involved
in circuitry guiding motivated behavior. Second, breakpoint
is used to quantify motivation and reinforcing efficacy
(Richardson and Roberts, 1996). Third, behaviorally relevant
stimuli can impact astrocyte morphology that can, in turn,
influence synaptic efficacy and neuronal responses to
salient stimuli (Laming et al, 2000). Though the potential
impact of EtOH-seeking behavior during testing cannot be
dissociated from astrocyte density, a significant correlation
was observed in both the operant and EtOH-IA cohorts that
differed markedly in operant responding.
Given the increased density of GFAPþ astrocytes in the
NAcore following EtOH abstinence, it was somewhat sur-
prising that neither ALDH1L1þ cell counts nor ALDH1L1
protein expression changed. These data suggest that increased
density only occurred in a subset of the NAcore astrocyte
population, which is consistent with earlier reports showing
that only a subset of ALDH1L1þ cells co-express GFAP
(Cahoy et al, 2008). Additionally, a similar finding of altered
GFAPþ astrocyte density, yet unchanged GFAP expression,
was previously observed in EtOH-dependent human brain
(Miguel-Hidalgo et al, 2002). While the specific ramifications
of increased GFAPþ astrocyte density concerning motivated
behavior remain unknown, it has been shown that increased
astrocyte density can mitigate the impact of neurotoxic
peroxide production that occurs during cytochrome P450-
mediated metabolism of EtOH (Desagher et al, 1996).
Additionally, it is important to note that our experiments
expressed Gaq-DREADDs under the GFAP promoter.
Astrocyte Communication Impacts Neural Physiology
and Behavior
Exactly how NAcore astrocytes contribute to the motivation
to self-administer EtOH is not presently clear. However, a
re-balancing of neuron-astrocyte bidirectional communica-
tion is likely to be an important aspect of this effect. This
form of communication has been extensively reviewed
(eg, Santello et al, 2012). In brief, the foundation of bidirec-
tional communication is that astrocytes both respond to
(Porter and McCarthy, 1996) and release (Parpura et al,
1994) transmitter, which ultimately impacts synaptic
plasticity and behavior (Parpura et al, 2012). Additionally,
bidirectional communication was also recently observed in
human brain preparations (Navarrete et al, 2013). Increased
[Caþþ ]i is both necessary and sufficient for most forms
of astrocytic transmitter release (Parpura et al, 1994). EtOH
can also increase astrocytic [Caþþ ]i and transmitter release
(Allen et al, 2002). Thus, it is intriguing that Gaq-DREADD
activation increased astrocytic [Caþþ ]i both ex vivo
(Agulhon et al, 2013) and in vitro (results here), and also
reduced the motivation for EtOH as shown by our data.
While the precise mechanisms that lie downstream of Gaq-
DREADD activation and that may underlie reduced break-
point remain unknown, it has been shown that increased
astrocytic [Caþþ ]i levels and subsequent glutamate release
occur after activation of endogenous Gaq-coupled receptors
(Woo et al, 2012). Further, the impact of astrocytic [Caþþ ]i
on transmitter release, and subsequent neuronal responses
have been reviewed (Santello et al, 2012). Nonetheless,
future studies are needed to identify if these mechanisms
and transmitter system are directly involved in the effects
reported here.
Others have also shown that astrocytes can shape behavior.
For example, cerebellar astrocyte optogenetic stimulation
activated purkinje neuron glutamate receptors, induced
synaptic plasticity, and modulated cerebellar-regulated
behaviors (Sasaki et al, 2012). Additionally, methampheta-
mine conditioned-stimulus effects were increased by
nucleus accumbens microinjection of astrocyte-conditioned
medium (Narita et al, 2006). Given that astrocyte-condi-
tioned medium can induce neural stem cell differentiation
into astrocytes (Narita et al, 2006), our data correlating
increased NAcore astrocyte density with increased motiva-
tion for EtOH breakpoint are especially intriguing.
Gap-Junction Hemichannel Pharmacology
A limitation of the present study is that gap-junction
hemichannel blockers exhibit affinity for other structurally
related channels, including the pannexin-1 containing
pannexons and the P2X7 receptor pore as well as the
connexin-containing gap channels and volume-regulated
anion channels (VRACs; Ye et al, 2009). Thus, gap-junction
hemichannel blockers are not astrocyte-specific. However,
the channels exhibit unique biophysical properties that can
influence pharmacological sensitivity under certain condi-
tions. For example, gap-junction channels couple neighbor-
ing cells, but the other hemichannels can open to the
extracellular space. Of those opening to the extracellular
space, the connexin-containing hemichannels are usually
closed under physiological conditions, as even brief opening
can be cytotoxic (Halassa et al, 2007). Further, hemichan-
nels are closed by EtOH (Adermark and Lovinger, 2006) or
increased [Caþþ ]i (Scemes et al, 2007). In contrast, the
pannexin-containing pannexons are open under physiolo-
gical conditions (Dahl and Harris, 2008) including increased
[Caþþ ]i (Scemes et al, 2007), and can exhibit approxi-
mately 5- to 10-fold more sensitivity to glycyrrhetinic
acidic-related synthetic derivatives; eg, 18-a, than connexin-
based channels (Bruzzone et al, 2005). EtOH can open both
the pannexin-containing channels (Locovei et al, 2006) and
VRAC (Allen et al, 2002). Thus, it is likely that the increased
EtOH breakpoint may have emanated from pannexin and/or
VRAC blockade. Future experiments can partially evaluate
this hypothesis by using the VRAC-selective blocker DCPIB.
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Despite this promiscuity, low mefloquine doses were
previously shown to preferentially block neuronal
channels (Cruikshank et al, 2004). Thus, while potential
additive effects of simultaneous neuronal and astrocytic
gap-junction hemichannel blockade cannot be cleanly
discerned, it is clear that neither the sucrose nor EtOH
breakpoints were altered by neuron-targeting mefloquine
doses. Because 18-a is not cell-selective, it is important
to note that both high-dose mefloquine and 18-a increased
the EtOH breakpoint to the same extent (data here),
given that microinjection of this same 18-a dose into the
rat prefrontal cortex increased EtOH preference to the
same extent as an astrocyte-specific toxin (Miguel-Hidalgo
et al, 2008). Together, these data suggest that blockade
of NAcore astrocytic gap-junction hemichannels increased
the motivation to self-administer EtOH after 3 weeks
abstinence.
Stimulating Astrocytes Decreased the Motivation for
Ethanol
Due to its effect on the EtOH breakpoint, Gaq-DREADD
activation can be conceptualized as the functional inverse of
blocking gap-junction hemichannels. One could test this
hypothesis by reversing the effect of Gaq-DREADD activa-
tion on breakpoint via microinjection of subthreshold doses
of gap-junction hemichannel blockers. Nonetheless, given
that astrocytic Gaq-DREADD activation facilitated ICSS,
this postulate is partially supported by studies showing that
NAcore gap-junction hemichannel blockers decreased ICSS
(Kokarovtseva et al, 2009). Further, the facilitation
of responding for ICSS observed following astrocytic Gaq-
DREADD activation could, by extension, underlie the
reduced EtOH breakpoint observed here because ICSS
thresholds are elevated during EtOH abstinence (Schulteis
et al, 1995). The Gaq-DREADD-mediated ICSS facilitation
exhibited an inverted U-shaped dose–response and was small
relative to cocaine, suggesting that future medications that
stimulate astrocytes in this manner may not possess high
abuse liability. Finally, the significance of being able to
selectively manipulate astrocytic signaling can be illustrated
by comparing our data to a recent report where
EtOH consumption was not affected by stimulation of Gaq-
DREADDs that were expressed in mouse NAcore neurons
(Cassataro et al, 2014).
CONCLUSION
Astrocytes can actively shape neuronal plasticity and func-
tion. This is the first study revealing a dichotomous role of
nucleus accumbens astrocytes in the motivation to self-
administer EtOH and responding for rewarding brain stimu-
lation. These data add to the rapidly growing appreciation
that, in addition to critical homeostatic functions, discrete
astrocyte populations can be manipulated to abate drug-
seeking behavior.
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